IASLC Oligometastatic NSCLC
In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such a...
16 Tammi 202429min
Maximizing Supportive Care in Lung Cancer
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss the importance of palliative care and psychological support for patients with lung cancer. Due to recent advances ...
26 Joulu 202343min
Lung Cancer in MENA: Clinical and Research Initiatives
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapi...
22 Joulu 202327min
IASLC Chronic Toxicity From Targeted Therapy
IASLC Chronic Toxicity From Targeted Therapy by IASLC
19 Joulu 202355min
LCC in Korean: Managing EGFR+ NSCLC
Lung cancer experts in Korea discuss the unique challenges they face when treating patients with lung cancer with EGFR and non-small cell lung cancer.
15 Joulu 202350min
New Options for Initial Treatment of EGFR Mutant NSCLC
In this episode, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, including how new data from FLAURA2 and MARIPOSA may in...
12 Joulu 202345min
Research from NACLC: Nutrition as Medicine and Lung Cancer Screening
IASLC Lung Cancer Considered host Dr. Narjust Florez interviews two researchers presenting at the North America Conference on Lung Cancer: Dr. Carolyn Presley is an Associate Professor in the Divisio...
8 Joulu 202343min
FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-...
30 Marras 202337min
